An Innovative, Prospective, Hybrid Cohort-Cluster Study Design to Characterize Dengue Virus Transmission in Multigenerational Households in Kamphaeng Phet, Thailand by Anderson, Kathryn B et al.
University of Rhode Island 
DigitalCommons@URI 
Cell and Molecular Biology Faculty Publications Cell and Molecular Biology 
7-2020 
An Innovative, Prospective, Hybrid Cohort-Cluster Study Design to 
Characterize Dengue Virus Transmission in Multigenerational 
Households in Kamphaeng Phet, Thailand 
Kathryn B. Anderson 
Darunee Buddhari 
Anon Srikiatkhachorn 
Gregory D. Gromowski 
Sopon Iamsirithaworn 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.uri.edu/cmb_facpubs 
Authors 
Kathryn B. Anderson, Darunee Buddhari, Anon Srikiatkhachorn, Gregory D. Gromowski, Sopon 
Iamsirithaworn, Alden L. Weg, Damon W. Ellison, Louis Macareo, Derek A T Cummings, In-Kyu Yoon, 
Ananda Nisalak, Alongkot Ponlawat, Stephen J. Thomas, Stefan Fernandez, Richard G. Jarman, Alan L. 
Rothman, and Timothy P. Endy 
American Journal of Epidemiology
© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of
Public Health. This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use,
please contact journalpermissions@oup.com.





An Innovative, Prospective, Hybrid Cohort-Cluster Study Design to Characterize
Dengue Virus Transmission in Multigenerational Households in Kamphaeng
Phet, Thailand
Kathryn B. Anderson∗, Darunee Buddhari, Anon Srikiatkhachorn, Gregory D. Gromowski,
Sopon Iamsirithaworn, Alden L. Weg, Damon W. Ellison, Louis Macareo, Derek A. T. Cummings,
In-Kyu Yoon, Ananda Nisalak, Alongkot Ponlawat, Stephen J. Thomas, Stefan Fernandez,
Richard G. Jarman, Alan L. Rothman, and Timothy P. Endy
∗ Correspondence to Dr. Kathryn B. Anderson, Department of Medicine, Upstate Medical University, 750 E. Adams Street,
Syracuse, NY 13210 (e-mail: andekath@upstate.edu).
Initially submitted August 14, 2018; accepted for publication January 9, 2020.
Difficulties inherent in the identification of immune correlates of protection or severe disease have challenged
the development and evaluation of dengue vaccines. There persist substantial gaps in knowledge about the
complex effects of age and sequential dengue virus (DENV) exposures on these correlations. To address these
gaps, we were conducting a novel family-based cohort-cluster study for DENV transmission in Kamphaeng Phet,
Thailand. The study began in 2015 and is funded until at least 2023. As of May 2019, 2,870 individuals in
485 families were actively enrolled. The families comprise at least 1 child born into the study as a newborn,
1 other child, a parent, and a grandparent. The median age of enrolled participants is 21 years (range 0–93
years). Active surveillance is performed to detect acute dengue illnesses, and annual blood testing identifies
subclinical seroconversions. Extended follow-up of this cohort will detect sequential infections and correlate
antibody kinetics and sequence of infections with disease outcomes. The central goal of this prospective study
is to characterize how different DENV exposure histories within multigenerational family units, from DENV-naive
infants to grandparents with multiple prior DENV exposures, affect transmission, disease, and protection at the
level of the individual, household, and community.
dengue virus; pathogenesis; prospective cohort study; Thailand; transmission
Abbreviations: DENV, dengue virus; ELISA, enzyme-linked immunosorbent assay; FlowNT, flow neutralization assay;
HAI, hemagglutination inhibition; IgG, immunoglobulin G; IgM, immunoglobulin M; JEV, Japanese encephalitis virus;
RT-PCR, reverse-transcriptase polymerase chain reaction; ZIKV, Zika virus.
Dengue virus (DENV) causes a significant burden of
disease throughout tropical and subtropical regions of the
world, with an estimated 390 million infections annually and
96 million illnesses (1). There is no effective antiviral for
DENV infection, and efforts to control the mosquito vector
Aedes aegypti have had incomplete success (2). The deve-
lopment of an effective tetravalent DENV vaccine therefore
remains an important priority, and several candidate vac-
cines are in development (3). A single vaccine (Dengvaxia;
Sanofi Pasteur, Lyon, France) has been licensed in over 20
countries, including the United States and European Union,
but is indicated only for use in people with proof of prior
DENV infection. This narrow indication and adverse safety
signals in vaccinated dengue-naive individuals has made
Dengvaxia uptake poor. Vaccine development and evalua-
tion have been impeded by critical gaps in our understanding
of DENV immunology and epidemiology (4).
Infection with any of the 4 DENV serotypes (DENV-1–4)
can cause a spectrum of outcomes from asymptomatic infec-
tion to dengue hemorrhagic fever or dengue shock syndrome.
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It has long been recognized that severe dengue illness is
more likely to occur in the setting of preexisting immunity to
DENV, derived either from placentally transferred maternal
antibody in infants or from a prior DENV infection (5, 6).
However, preexisting immunity to DENV serotypes has also
been shown to be protective against severe disease (7, 8).
It is not clear when and how preexisting immunity could
predispose toward or protect from illness following a subse-
quent DENV infection, a knowledge gap that has hindered
the development of dengue vaccines and, increasingly, the
development of antivirals and immunotherapeutics.
The cross-reactivity and uncertainty inherent in inter-
preting DENV serotype-specific infection histories based
upon serological data render cross-sectional studies, and
even short-term prospective studies, suboptimal for charac-
terizing factors associated with dengue pathogenesis and
protective immunity. The long-term prospective cohort-
cluster study described herein will follow newborn infants
and their multigenerational family units through successive
DENV infections and over several years, characterizing their
dynamic immunological profiles over time and evaluating
factors associated with asymptomatic or severe infection
outcomes. Nested cluster-based studies of enrolled house-
holds experiencing an incident acute dengue illness will
allow focused surveillance of individuals at high risk of
exposure, some of whom will become infected and thus
facilitate studies of immunological correlates of protection
and severe disease. We have previously observed that DENV
transmission is tightly focused within and immediately
surrounding the home of an infectious individual (9, 10).
Thus, family units provide a unique opportunity to efficient-
ly study the outcomes of exposure to a given DENV serotype
in a multigenerational group of people with shared genetics
and overlapping DENV exposure histories.
The objectives and associated hypotheses for the study are
as follows:
• Objective 1: To correlate pre- and postinfection immuno-
logical profiles with disease outcomes across sequential
DENV infections in children and adults. Hypothesis 1:
Preexisting immunological profiles can be identified that
serve as correlates of disease (11) and correlates of pro-
tection for subsequent DENV infections (12). Hypothesis
2: The sequence of DENV serotype exposures is associa-
ted with risk of severe dengue illness upon subsequent
infection (13).
• Objective 2: To define potential disease-modifying
roles of maternally derived DENV immunity in infants.
Hypothesis: Newborns acquire maternal immunity that
modulates the clinical outcome of DENV infection
within definable windows of time and/or within definable
immunological profiles (14).
• Objective 3: To define the clinical and immunological
outcomes of sequential DENV infections in adults with
multiple prior DENV exposures. Hypothesis 1: Adults
in DENV-endemic areas experience periodic subclini-
cal infection resulting in immunological boosting and
maintenance of cross-protective immunity (8). Hypothe-
sis 2: Immunosenescence in older adults (aged ≥50 years)
leads to an increased risk for symptomatic DENV infec-
tion due to waning protective immunity.
• Objective 4: To identify risk factors for DENV trans-
mission in household units. Hypothesis: The force of
infection (i.e., incidence among susceptible individuals)
for DENV in households and in communities will differ




This ongoing, prospective longitudinal cohort-cluster
study will follow a cohort of 500 multigenerational family
units residing in Kamphaeng Phet province, Thailand. The
study began in 2015, will continue through at least 2023, and
was actively following 2,870 individuals in 485 families
as of May 2019. The study enrolls pregnant women and
their multigenerational family units, including their new-
born infant at the time of delivery (Figure 1). Through active
surveillance, cohort subjects with symptomatic DENV
infection are identified, and subsequent virus transmission
to other family members is evaluated via household-based
cluster investigations. Scheduled blood testing is performed
annually to detect subclinical infections and to provide base-
line and periodic blood samples for immunological analysis.
The methods of this observational study are further detailed
in accordance with Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guidelines (14).
Setting
The study is conducted in Kamphaeng Phet province
in north-central Thailand (Figure 2). Kamphaeng Phet is
located 350 km north of Bangkok and has a population of
700,000 people in a mostly rural to semirural setting. Clini-
cal partners for this study are the 410-bed Kamphaeng Phet
Provincial Hospital, situated in the central Muang (capi-
tal) district, and the 90-bed Khanu Woralaksaburi district
hospital, located approximately 60 km southeast of Muang
district. Additionally, pregnant women are recruited from
among 52 basic village health centers located in Muang and
Khanu Woralaksaburi districts.
Enrollment
Enrollment of households is contingent upon the identifi-
cation of eligible women in the third trimester of pregnancy,
who are briefed and screened during antenatal visits. If the
pregnant woman consents to participate, her family mem-
bers are briefed at their home. Inclusion criteria include:
1) residence in Kamphaeng Phet province with no plans to
move and 2) at least 4 family members’ consent to partici-
pate, including the pregnant woman (aged ≥15 years), her
newborn, at least 1 other child <18 years of age, and 1 adult
aged ≥50 years. Exclusion criteria include: 1) congenital or
acquired immunodeficiency, 2) immunosuppressive therapy
within the preceding 6 months, 3) chronic illness that might
interfere with study conduct, and 4) receipt of blood products
in the past 3 months. Written informed consent is obtained,
as is signed assent for children older than 7 years.
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Figure 1. Flowchart of study activities for a prospective family cohort study in Kamphaeng Phet, Thailand, 2015–2019. DENV, dengue virus;
RT-PCR, reverse-transcriptase polymerase chain reaction.
All enrolled subjects have a demographic and clinical
questionnaire administered (Table 1) and a blood sample
drawn for laboratory testing (Table 2). Study staff perform
Global Positioning System (GPS) mapping of the home
using a hand-held device. When enrolled pregnant women
go into labor, study staff collect clinical information about
the delivery and coordinate collection of cord blood.
Approximately 22 mL of cord blood is collected by the
hospital nurse/physician directly from the umbilical cord
after delivery.
Routine (annual) follow-up
All subjects have an annual follow-up questionnaire
administered and a routine blood sample drawn by study
staff. For 2015–2019, routine follow-up was performed
between April and June, prior to the peak DENV transmis-
sion (rainy) season in this region. Thus, for some individuals,
the first routine follow-up occurred within months of being
enrolled. If subjects were unavailable during this period,
for example, due to travel outside of the study area, the
routine follow-up occurred as early thereafter as possible.
Beginning in late 2019, follow-up activities will be shifted to
occur at the end of the DENV season (roughly November–
December) to maximize the capture of seroconversions
following infection (15).
Active surveillance and illness investigations
Active and passive surveillance activities for febrile ill-
nesses are conducted year-round. Participants are instructed
to contact study staff if any enrolled subject in the household
develops fever. Additionally, study staff contact subjects
(via telephone, text, or home visit) weekly to inquire as to
whether an acute febrile illness was missed since the previ-
ous contact. The threshold for initiating an illness investiga-
tion in a study subject is a history of reported fever within
the previous 7 days or measured temperature of ≥38◦C.
Additionally, health-care providers are requested to contact
study staff when clinic visits or hospitalizations occur related
to acute febrile episodes in enrolled subjects.
Evaluation of a febrile illness involves collection of an
acute blood sample and 2 convalescent blood samples: one
convalescent sample at 14 days and another at 28 days after
acute sample collection. Clinical information—including
onset, duration, and severity of symptoms—is recorded by
the study team using a prestructured questionnaire at each
visit. Study staff inform Kamphaeng Phet Provincial Public
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Figure 2. Map of Kamphaeng Phet province, indicating location within Thailand (A) (source: Wikipedia) and the locations of enrolled households
(B) (source: Google Earth Pro) for a prospective family cohort study in Kamphaeng Phet, Thailand, 2015–2019. Spatial resolution of the map
image is intentionally low, to preclude identification of individual homes.
Health Office about any acute DENV reverse-transcriptase
polymerase chain reaction (RT-PCR)-positive cases within
1–2 days, and they then apply antivector measures per Mi-
nistry standards.
Household contact dengue investigation
DENV RT-PCR is performed on acute specimens from
illness investigations within 24–48 hours of collection. Con-
firmation of an acute DENV infection by RT-PCR triggers
an expanded evaluation of all enrolled members of the home
(a “household investigation”). Household investigations are
typically initiated the same day as or day after RT-PCR
results are obtained, but they might be delayed up to 3 days
over weekends or holidays. Household contacts have blood
drawn and clinical data collected on days 0, 14, and 28,
regardless of whether or not they are ill.
Laboratory testing
Acute blood samples from illness investigations are tested
by DENV RT-PCR within 1–2 days of collection (16). The
day-0 blood sample from household investigations (and
a household contact’s acute blood sample, if applicable)
are also tested by DENV RT-PCR. Serological diagnosis
of acute DENV infection is accomplished using enzyme-
linked immunosorbent assay (ELISA) and hemagglutination
inhibition (HAI) assays (17). Immunoglobulin M (IgM)- and
immunoglobulin G (IgG)-capture ELISAs for DENV and
HAI assays to detect antibodies to DENV-1–4 are performed
on acute and convalescent specimens from illness and
household investigations, testing for DENV and Japanese
encephalitis virus (JEV) antibodies (18). Dengue IgM
of ≥40 U with a DENV IgM-to-IgG ratio of ≥1.8 is defined
as “primary” DENV infection; a ratio of <1.8 is defined
as “secondary” DENV infection. Further, a 2-fold increase
in dengue IgG with an absolute value of ≥100 U indicates
secondary infection in the absence of dengue IgM of ≥40
U (18). For HAI, a 4-fold rise in antibody titers for any
DENV serotype (greater than or equal to the rise observed
for JEV) indicates acute infection. A titer of ≥1:2,560 to
any DENV serotype is associated with secondary DENV
infection; a maximum titer of ≤1:1,280 is associated with
primary infection. Seroconversion by either HAI or ELISA
constitutes serological diagnosis of acute DENV infection
in the cohort.
For routinely collected specimens (enrollment and annual
follow-up), DENV neutralizing antibody titers are measured
using a flow cytometry-based neutralization assay (FlowNT)
(19). Fifty percent neutralization titers (FlowNT50) in enroll-
ment specimens are used to determine baseline serostatus,
where “DENV-naive” indicates enrollment FlowNT50 titers
of <40 for DENV types 1–4; “monotypic” indicates a titer
of ≥40 for a single DENV type; and “multitypic” indicates
titers of 40 for 2 or more DENV types. Seroconversion
is defined as at least a 4-fold rise in FlowNT50 between
specimens, for at least 1 DENV type. For the purposes of
the present work, seroconversion data are based upon results
from HAI assays (FlowNT50 data for the entire cohort are
pending at the time of publication). Seroconversion by HAI
is defined as a 4-fold rise in titers to at least 1 DENV type,
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greater than or equal to any rise observed for JEV, for paired
specimens.
Entomological procedures
Mosquito collections are performed periodically at the
homes of cohort families to coincide with annual (routine)
follow-up activities and during all household investigations.
Environmental data are collected, such as house infras-
tructure features, number and types of man-made water
storage containers, and other potential mosquito-breeding
sites. Adult Aedes mosquitoes are collected from within and
around the home using adult mosquito traps (BG-Sentinel;
Biogents, Regensburg, Germany) on days 0 and 14 of the
contact investigation. Traps are placed early in the morning
and retrieved the same evening, thus reflecting 2 single days
of mosquito collections to correspond with the timing of
acute and convalescent blood specimens. Mosquito samples
retrieved from each trap are examined under a microscope
to identify their sex and species. Aedes females are subse-
quently screened for DENV infection by RT-PCR.
Mote deployment
Proximity-detecting motes are deployed during house-
hold investigations and sporadically during annual follow-
up to identify movement patterns in the cohort. Crossbow’s
TelosB motes (TPR2400; Crossbow Inc., San Jose, Califor-
nia) are small electronic devices that detect when they are
within range of another mote and log the amount of time
that they are in proximity. Information recorded by a mote
can be used to determine the amount of time spent at home,
the total number of close contacts a subject makes with
other subjects, the duration of such contacts, and whether
a subject makes contact with certain individuals more often
than others (20). These contact patterns are used to inform
models of virus transmission within the family unit.
Sample-size calculations
Based on previous studies conducted in Kamphaeng Phet,
we assumed an average annual incidence of DENV infection
of 7% (21). We therefore anticipate that 7% of children born
into the study as infants will experience primary DENV
infection each year (220 over 8 years) and that 7% of siblings
younger than 18 years of age will experience primary or
secondary DENV infection (220 siblings younger than 18
years, 220 adults aged <50 years, and 220 adults aged
≥50 years over the 8 year study period). Among these,
approximately half of infections will be subclinical infec-
tions and half symptomatic infections (22). Assuming that
one-half of infections in siblings aged less than 18 years
will be secondary DENV infections and all adult infections
will be secondary, we expect 550 secondary infections du-
ring the 8-year period. We will thus have a power of 83%
to detect a 75-unit absolute difference in serotype-specific
(preinfection) geometric mean titers between individuals
experiencing secondary symptomatic and subclinical DENV
infections during the study (objective 1).
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In the present work, seroconversion rates are presented
using a denominator of person-months, representing the
summed intervals between enrollment and follow-up. Con-
tinuous measurements, such as entomological indices, will
be compared between groups using analysis of variance
(ANOVA) or ANOVA on ranks, as appropriate, based on
assessment of normality. Proportional data, such as the pro-
portion of infections that were symptomatic, are compared
between groups using χ2 analyses.
In planned future analyses, multivariate analyses will be
conducted using generalized estimating equations (GEE) or
hierarchical generalized additive models (HGAM), which
will include random effects to control for repeated measures
within individuals, households, and districts. Age-stratified
seroprevalence data, derived from the serotype-specific neu-
tralizing antibody data for all participants on enrollment,
will be used to estimate the force of infection for DENV
infection using catalytic models as previously described
(23). Spatial heterogeneity in the force of infection will be
assessed by subdistrict. Serotype-specific force of infection
will be estimated, with the infecting serotype for RT-PCR-
negative and subclinical infections inferred based upon the
dominant DENV serotypes circulating in a given individ-
ual’s community in a given year. This approach is supported
by prior work indicating highly focal transmission of DENV
serotypes and strains in households and communities (9).
Sensitivity analyses will explore the impact of these assump-
tions on the estimates of serotype-specific and overall FOI.
Potential confounders
A major area of interest for this study is the relationship
between preexisting dengue immunity and the risk of dengue
illness with infection (compared with asymptomatic infec-
tion). Age is an important confounder of this association
because adults are more likely to have accumulated DENV
immunity through multiple prior exposures, and adults have
also been shown to have an increased risk of clinical illness
with DENV infection (24). Other important confounders
might include the presence of medical comorbidities and
history of JEV vaccination. All of these variables will be
recorded upon enrollment and updated annually. Given that
the timing of routine follow-up activities varied during the
study period, we will control for the month of follow-up
given the seasonality of DENV transmission in the study
area. Infecting serotype is an important confounder, related
both to prior exposure history and the risk of illness. Analy-
sis will be adjusted for, or stratified by, all of the above con-
founders in generalized estimating equations or hierarchical
generalized additive models as described above.
A second major area of interest for this study is the
interplay between individual, household, and community
factors and the force of DENV infection within the house-
hold. For this analysis, we will stratify on the circulating
serotype, calculating the serotype-specific force of infec-
tion. An additional possible confounder will be the timing
and extent of mosquito-control measures undertaken in and
around the home following diagnosis of DENV infection, as
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Figure 3. Age and sex composition of the actively enrolled participants in the study, as of May 2019, for a prospective family cohort study in
Kamphaeng Phet, Thailand, 2015–2019. NB, newborn.
routinely performed by the Thai Ministry of Health. For each
household investigation, we will seek to gather information
on the timing and extent of mosquito control efforts. If this
proves to be an important confounder, we will control for it
in analysis.
Ethical approvals
This study was approved by Thailand Ministry of Public
Health Ethical Research Committee, Siriraj Ethics Com-
mittee on Research Involving Human Subjects, Institutional
Review Board for the Protection of Human Subjects State
University of New York Upstate Medical University, and
Walter Reed Army Institute of Research Institutional Review
Board (protocol #2119).
RESULTS
Enrollment and retention of study participants
The family cohort study began enrollment in September
2015; 1,216 women in their third trimester of pregnancy
were briefed during their routine antenatal care visits, and
of these, 811 indicated an interest in participating, and 552
met inclusion criteria for enrollment. As of May 2019, a
total of 3,469 individuals in 551 families have been enrolled
(Web Figure 1, available at https://academic.oup.com/aje);
599 individuals have been lost to follow-up or withdrawn for
reasons of: moved out of study area (245), failure to collect
cord blood (183), new failure to meet inclusion criteria (79;
e.g., less than 3 family members in home, new diagnosis of
immunodeficiency), participant voluntarily withdrew (59),
and death unrelated to study procedures (33).
Characteristics of study participants
The median age of participants at enrollment was 21 years
(range, 0–93 years) (Figure 3). Among pregnant women, the
median age was 24 years (range, 15–42 years), and among
family members (i.e., excluding the pregnant woman and her
newborn) the median age was 29 years (range, 0–93 years).
Of all enrolled participants, 56.9% were female, with 49.3%
among enrolled family members.
Enrollment serostatus
Of the 774 individuals enrolled in 2015, 416 completed
the first annual follow-up in 2016. The remaining individuals
completed follow-up in 2017. Enrollment neutralizing anti-
body titers DENV-1–4 are available for these 416 individuals
and pending for the rest of the cohort. FlowNT50 testing of
enrollment specimens demonstrated seroprevalence rates of
89% for newborns (as detected in cord blood), reflecting
maternally transferred antibody and, possibly, some in utero
infections (Figure 4). Seroprevalence decreased to 46% for
children aged 0–5 years and increased steadily thereafter
until 100% of individuals aged 30 years or older demon-
strated multitypic immunity to DENV.
Illness and household investigations
A total of 295 illness investigations were conducted
between September 2015 and May 2019 among 243 indi-
viduals (Figure 5). Illness investigations confirmed 33 acute
infections by DENV RT-PCR (11 DENV-1, 8 DENV-2, 4
DENV-3, and 10 DENV-4), prompting 29 household inves-
tigations (4 individuals lived in the same home as another






/aje/article/189/7/648/5714864 by guest on 22 D
ecem
ber 2020
Family Cohort Study for Dengue Virus Infection 655
Figure 4. Enrollment serostatus of 416 study participants enrolled in 2015, based upon flow-based cytometry testing for neutralizing antibodies
to dengue virus (DENV)-1–4 serotypes, Kamphaeng Phet, Thailand, 2015–2019. “Naive" indicates that an individual lacked detectable antibodies
to all 4 serotypes (titer: <1:40); “monotypic” indicates a positive titer to a single DENV serotype; “multitypic” indicates a positive titer for ≥2 DENV
serotypes.
person with a confirmed DENV infection); 43 DENV
infections were identified during household investigations,
including 8 RT-PCR-positive and 35 RT-PCR-negative
(serologically confirmed) infections. The associated infec-
tion rate in household contacts was therefore 26.7% (43
DENV infections/161 household contacts), consistent with
the high household attack rate reported in prior studies
in the area (9). Of acute DENV infections in household
contacts, 32.5% (13/40) were symptomatic; young children
(aged 0–5 years) were the most likely to experience symp-
tomatic DENV infection (50.0%), followed by older chil-
dren (6–17 years) and young adults (18–30 years) (33.3%
(3/9) and 40.0% (4/10), respectively). There were no symp-
tomatic infections detected among household contacts
aged 31–50 years (0/4). Seven DENV infections occurred
in adults aged 50 years or older, of which 1 infection
was symptomatic (14.2%); 80.0% of DENV infections in
children aged 0–5 years were primary DENV infections,
55.6% in children aged 5–17 years, and 50.0% in adults
aged 16–50 years. Interestingly, in household contacts aged
≥51 years, 71.4% of DENV infections were determined to
be “primary” infections by ELISA and/or HAI.
Routine follow-up and seroconversions
The median interval of time between enrollment and
the first routine follow-up was 13 months (range, 2–20
months), between the first and second routine follow-up was
11 months (range, 5–15 months), and between the second
and third routine follow-up was 10 months (range, 6–16
months). In total, 74,343 person-months of observation were
accrued between September 2015 and July 2018. We are
in the process of completing HAI and FlowNT50 testing
to determine seroconversion rates for the second and third
years of follow-up for enrolled individuals. Thus, data are
presented for seroconversion rates following the first year
of enrollment for the cohort participants enrolled in 2015,
2016, and 2017 (Figure 6).
The overall seroconversion rates for the first year of
follow-up were: 1.04 DENV infections/100 person-months
(95% confidence interval: 0.66, 1.41) for those enrolled
in 2015, 0.21/100 person-months (95% confidence inter-
val: 0.15, 0.28) for those enrolled in 2016, and 0.49/100
person-months (95% confidence interval: 0.35, 0.63) for
those enrolled in 2017. For cohort participants enrolled
in 2015 and 2017, the highest rate of seroconversion was
observed in those aged 18–29 years; for those enrolled in
2016, the highest rate was observed in those aged 6–17 years.
DISCUSSION
Recent issues with the safety and immunogenicity of
DENV vaccines highlight our limited understanding of how
multitypic immune protection from DENV infection and
illness is naturally shaped during sequential and accumu-
lated DENV exposures (4). Even less understood are factors
associated with the durability of protection into adulthood/
advanced age, such as the role of boosting in maintaining
protective immunity. The prospective study described
herein, being conducted in a hyperendemic and well-
characterized locale for DENV transmission in Thailand,
aims to address these and other critical gaps in our under-
standing of DENV transmission and pathogenesis (Figure 7).
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Figure 5. Results from illness and household investigations, including dengue virus (DENV) serotype and primary/secondary infection status
of detected infections, Kamphaeng Phet, Thailand, 2015–2019. Note that 4 reverse-transcriptase polymerase chain reaction (RT-PCR)-positive
individuals resided in the same house as other tested-positive individuals; thus, 29 household investigations from 33 cases.
We describe a novel family-based cohort study that
will follow newborn infants and their multigenerational
family units prospectively for the occurrence of sequential
DENV infections. The study is an innovative hybrid of
cohort and cluster study methodologies, involving the
routine characterization of immune profiles prior to and
following sequential DENV infections, while employing
febrile illness cluster investigations to maximize the capture
and characterization of associated infections in the home.
These associated infections will manifest across a clinical
spectrum from asymptomatic DENV infection to severe
disease, allowing the study of correlates of protection and
illness (11). The study is currently funded through 2023
(allowing up to 8 years of follow-up); however, it will
ideally continue for many years beyond that, permitting the
extended characterization of DENV infections and immune
profile dynamics in the cohort.
In the first 3 years of the study, seroconversions to DENV
occurred across all age groups, from neonates to octogena-
rians. This is noteworthy given that dengue has typically
been studied as a pediatric disease in hyperendemic locales
such as Thailand. The mean age of DENV infection is
increasing in Thailand (25) and across Asia (24), and so
future studies in this cohort will consider the durability of
type-specific DENV immunity, the potential for immunose-
nesence with aging, and differences in the clinical presenta-
tion of dengue between children, adults, and the elderly. The
capture of instances of immunological boosting is suggested
by the relatively high rate of “primary” infection in adults
aged >50 years, per standard serological diagnostic criteria.
We are developing immunological and statistical criteria
to discriminate between boosting events and novel DENV
serotype exposures, which will inform our understanding
of the natural mechanisms promoting the maintenance of
protective immunity in this population.
Future analyses will address the duration of and factors
associated with protection from clinical illness afforded by
maternal antibodies in the first year of life. This knowledge
can inform the identification of optimal ages for DENV vac-
cination, ideally targeting a window of time associated with
minimal interference from maternally derived immunity and
with maximal numbers of dengue illnesses averted. The
identification of subclinical DENV infections in the setting
of waning maternal antibodies in the first year of life poses a
challenge, because for these infants “seroconversion” might
not manifest as a rise in antibody titers but rather as a “failure
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Figure 6. Seroconversion rate (per 100 person-months) according to age group and enrollment cohort, Kamphaeng Phet, Thailand, 2015–2019.
Seroconversion was defined as a 4-fold or greater rise in antibody titers to any dengue virus serotype by hemagglutination inhibition (without
a higher rise in Japanese encephalitis virus titers) when comparing 2 routinely collected specimens collected, on average, 1 year apart. Error
bars represent 95% confidence intervals for estimated rates.
to decay.” Therefore, the current reported seroconversion
rate in infants is likely an underestimate. We are developing
statistical algorithms to facilitate the serological diagnosis of
DENV infection in infants, accounting for the rate of decay
of maternal antibody.
The early years of this study have encountered some
challenges. Unknown at the time of study inception, we now
recognize that Zika virus (ZIKV) has been in circulation in
Thailand for at least several years (26). The cocirculation
of JEV and DENV and high levels of JEV vaccination have
complicated the serological diagnosis of DENV infection
in Thailand for decades (18, 27). The addition of potential
ZIKV exposure to this complex serological milieu makes the
diagnosis of DENV infection in the study area more chal-
lenging. Serological assays have historically demonstrated
poor specificity for distinguishing DENV and ZIKV infec-
tions; however, assays such as the NS1 blockade-of-binding
ELISA for ZIKV show promise (28) and are being evalua-
ted for possible incorporation into the study. The ability to
study newborns longitudinally through sequential incident
flavivirus infections (and JEV vaccination) should permit
invaluable insights into immunological, epidemiologic,
and clinical interactions between DENV, ZIKV, and JEV.
There are multiple sources of potential bias in the study.
There is selection bias by nature of the study design, because
enrollment is restricted to multigenerational families. We
will attempt to control for this with age-adjusted analyses.
There might be sampling bias—individuals and families
with histories of DENV infection could be more motivated
to participate. We have noted that adult men are less likely
to enroll and that adults in general have been less likely to
volunteer febrile illnesses (these illnesses are more often
detected by study staff phone call than by participant-
initiated report). We are seeking to address this potential
bias by providing educational materials and study results
to families, emphasizing the burden of DENV infection in
adults in the study area. We have shifted study activities
to occur primarily in the evenings in order to increase
participation by working adults. Finally, generalizability of
study results might be reasonable within Southeast Asia but
more limited in countries without a comparably high force
of infection or without similar flaviviruses in cocirculation
(i.e., the Americas).
In summary, this family cohort study for DENV transmis-
sion in Kamphaeng Phet, Thailand, uses a novel multigener-
ational and longitudinal study design to address fundamental
questions in DENV epidemiology and pathogenesis. The
study of preexposure immune profiles across all ages will
inform correlates of protection and disease severity, with
implications for the development of DENV vaccines and
therapeutics. The focus on dengue at the household level will
help define the full burden of dengue for families and com-
munities. Finally, this study should provide unprecedented
epidemiologic data on factors associated with the force of
infection for DENV and thereby identify opportunities for
population-level interventions to disrupt transmission.
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Figure 7. Lessons learned from the Kamphaeng Phet family
cohort study for dengue virus (DENV) transmission in households,
Thailand, 2015–2019.
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